Cargando…

Triheptanoin Protects Motor Neurons and Delays the Onset of Motor Symptoms in a Mouse Model of Amyotrophic Lateral Sclerosis

There is increasing evidence that energy metabolism is disturbed in Amyotrophic Lateral Sclerosis (ALS) patients and animal models. Treatment with triheptanoin, the triglyceride of heptanoate, is a promising approach to provide alternative fuel to improve oxidative phosphorylation and aid ATP genera...

Descripción completa

Detalles Bibliográficos
Autores principales: Tefera, Tesfaye W., Wong, Yide, Barkl-Luke, Mallory E., Ngo, Shyuan T., Thomas, Nicola K., McDonald, Tanya S., Borges, Karin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5001695/
https://www.ncbi.nlm.nih.gov/pubmed/27564703
http://dx.doi.org/10.1371/journal.pone.0161816
_version_ 1782450466221719552
author Tefera, Tesfaye W.
Wong, Yide
Barkl-Luke, Mallory E.
Ngo, Shyuan T.
Thomas, Nicola K.
McDonald, Tanya S.
Borges, Karin
author_facet Tefera, Tesfaye W.
Wong, Yide
Barkl-Luke, Mallory E.
Ngo, Shyuan T.
Thomas, Nicola K.
McDonald, Tanya S.
Borges, Karin
author_sort Tefera, Tesfaye W.
collection PubMed
description There is increasing evidence that energy metabolism is disturbed in Amyotrophic Lateral Sclerosis (ALS) patients and animal models. Treatment with triheptanoin, the triglyceride of heptanoate, is a promising approach to provide alternative fuel to improve oxidative phosphorylation and aid ATP generation. Heptanoate can be metabolized to propionyl-CoA, which after carboxylation can produce succinyl-CoA and thereby re-fill the tricarboxylic acid (TCA) cycle (anaplerosis). Here we tested the hypothesis that treatment with triheptanoin prevents motor neuron loss and delays the onset of disease symptoms in female mice overexpressing the mutant human SOD1(G93A) (hSOD1(G93A)) gene. When oral triheptanoin (35% of caloric content) was initiated at P35, motor neuron loss at 70 days of age was attenuated by 33%. In untreated hSOD1(G93A) mice, the loss of hind limb grip strength began at 16.7 weeks. Triheptanoin maintained hind limb grip strength for 2.8 weeks longer (p<0.01). Loss of balance on the rotarod and reduction of body weight were delayed by 13 and 11 days respectively (both p<0.01). Improved motor function occurred in parallel with alterations in the expression of genes associated with muscle metabolism. In gastrocnemius muscles, the mRNA levels of pyruvate, 2-oxoglutarate and succinate dehydrogenases and methyl-malonyl mutase were reduced by 24–33% in 10 week old hSOD1(G93A) mice when compared to wild-type mice, suggesting that TCA cycling in skeletal muscle may be slowed in this ALS mouse model at a stage when muscle strength is still normal. At 25 weeks of age, mRNA levels of succinate dehydrogenases, glutamic pyruvic transaminase 2 and the propionyl carboxylase β subunit were reduced by 69–84% in control, but not in triheptanoin treated hSOD1(G93A) animals. Taken together, our results suggest that triheptanoin slows motor neuron loss and the onset of motor symptoms in ALS mice by improving TCA cycling.
format Online
Article
Text
id pubmed-5001695
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-50016952016-09-12 Triheptanoin Protects Motor Neurons and Delays the Onset of Motor Symptoms in a Mouse Model of Amyotrophic Lateral Sclerosis Tefera, Tesfaye W. Wong, Yide Barkl-Luke, Mallory E. Ngo, Shyuan T. Thomas, Nicola K. McDonald, Tanya S. Borges, Karin PLoS One Research Article There is increasing evidence that energy metabolism is disturbed in Amyotrophic Lateral Sclerosis (ALS) patients and animal models. Treatment with triheptanoin, the triglyceride of heptanoate, is a promising approach to provide alternative fuel to improve oxidative phosphorylation and aid ATP generation. Heptanoate can be metabolized to propionyl-CoA, which after carboxylation can produce succinyl-CoA and thereby re-fill the tricarboxylic acid (TCA) cycle (anaplerosis). Here we tested the hypothesis that treatment with triheptanoin prevents motor neuron loss and delays the onset of disease symptoms in female mice overexpressing the mutant human SOD1(G93A) (hSOD1(G93A)) gene. When oral triheptanoin (35% of caloric content) was initiated at P35, motor neuron loss at 70 days of age was attenuated by 33%. In untreated hSOD1(G93A) mice, the loss of hind limb grip strength began at 16.7 weeks. Triheptanoin maintained hind limb grip strength for 2.8 weeks longer (p<0.01). Loss of balance on the rotarod and reduction of body weight were delayed by 13 and 11 days respectively (both p<0.01). Improved motor function occurred in parallel with alterations in the expression of genes associated with muscle metabolism. In gastrocnemius muscles, the mRNA levels of pyruvate, 2-oxoglutarate and succinate dehydrogenases and methyl-malonyl mutase were reduced by 24–33% in 10 week old hSOD1(G93A) mice when compared to wild-type mice, suggesting that TCA cycling in skeletal muscle may be slowed in this ALS mouse model at a stage when muscle strength is still normal. At 25 weeks of age, mRNA levels of succinate dehydrogenases, glutamic pyruvic transaminase 2 and the propionyl carboxylase β subunit were reduced by 69–84% in control, but not in triheptanoin treated hSOD1(G93A) animals. Taken together, our results suggest that triheptanoin slows motor neuron loss and the onset of motor symptoms in ALS mice by improving TCA cycling. Public Library of Science 2016-08-26 /pmc/articles/PMC5001695/ /pubmed/27564703 http://dx.doi.org/10.1371/journal.pone.0161816 Text en © 2016 Tefera et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Tefera, Tesfaye W.
Wong, Yide
Barkl-Luke, Mallory E.
Ngo, Shyuan T.
Thomas, Nicola K.
McDonald, Tanya S.
Borges, Karin
Triheptanoin Protects Motor Neurons and Delays the Onset of Motor Symptoms in a Mouse Model of Amyotrophic Lateral Sclerosis
title Triheptanoin Protects Motor Neurons and Delays the Onset of Motor Symptoms in a Mouse Model of Amyotrophic Lateral Sclerosis
title_full Triheptanoin Protects Motor Neurons and Delays the Onset of Motor Symptoms in a Mouse Model of Amyotrophic Lateral Sclerosis
title_fullStr Triheptanoin Protects Motor Neurons and Delays the Onset of Motor Symptoms in a Mouse Model of Amyotrophic Lateral Sclerosis
title_full_unstemmed Triheptanoin Protects Motor Neurons and Delays the Onset of Motor Symptoms in a Mouse Model of Amyotrophic Lateral Sclerosis
title_short Triheptanoin Protects Motor Neurons and Delays the Onset of Motor Symptoms in a Mouse Model of Amyotrophic Lateral Sclerosis
title_sort triheptanoin protects motor neurons and delays the onset of motor symptoms in a mouse model of amyotrophic lateral sclerosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5001695/
https://www.ncbi.nlm.nih.gov/pubmed/27564703
http://dx.doi.org/10.1371/journal.pone.0161816
work_keys_str_mv AT teferatesfayew triheptanoinprotectsmotorneuronsanddelaystheonsetofmotorsymptomsinamousemodelofamyotrophiclateralsclerosis
AT wongyide triheptanoinprotectsmotorneuronsanddelaystheonsetofmotorsymptomsinamousemodelofamyotrophiclateralsclerosis
AT barkllukemallorye triheptanoinprotectsmotorneuronsanddelaystheonsetofmotorsymptomsinamousemodelofamyotrophiclateralsclerosis
AT ngoshyuant triheptanoinprotectsmotorneuronsanddelaystheonsetofmotorsymptomsinamousemodelofamyotrophiclateralsclerosis
AT thomasnicolak triheptanoinprotectsmotorneuronsanddelaystheonsetofmotorsymptomsinamousemodelofamyotrophiclateralsclerosis
AT mcdonaldtanyas triheptanoinprotectsmotorneuronsanddelaystheonsetofmotorsymptomsinamousemodelofamyotrophiclateralsclerosis
AT borgeskarin triheptanoinprotectsmotorneuronsanddelaystheonsetofmotorsymptomsinamousemodelofamyotrophiclateralsclerosis